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Abstract The mobifization of iron from intracellular ferritin by 
ascorbic acid has been analysed in sltu by electron paramagentic 
resonance (EPR) spectroscopy. EPR enables a distinction 
between ferritins and other Fe3+-binding cellular components. 
The ordered iron core of ferritin gives rise to a resonance signal 
which can be observed only at temperatures above 50 K. In the 
present study we clearly demonstrate that ascorblc acid is 
capable of mobilizing iron from ferritin in the cellular system by 
reduction of the ferric ion core in neuroblastoma SK-N-SH cells. 
This mechanism ay open new ways in the therapy of this hardly 
curable tumor in stage IV, especially in combination with some 
cytostatic drugs. 
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1. Introduction 
Elevated ferritin levels in the serum of cancer patients are 
commonly used as a tumour marker to get informations 
about the size, mass and stage of the tumour. This may be 
true for a diversity of cancers like head and neck [1], lung [2], 
liver [3,4], breast [5], bladder [6] and renal cancer [7] as well as 
for teratoblastoma [8] and Morbus Hodgkin [9]. The serum 
ferritin level is also known to be a tumour marker in neuro- 
blastoma patients [10]. In addition, as it could be demon- 
strated for other tumour cells, neuroblastoma tissue contains 
high amounts of ferritin intracellularly [11,12]. 
Intracellular ferritin may either function as an iron storage 
protein to support iron dependent enzymatic activity or as an 
iron scavenger to prevent oxidative damage [13]. If iron is 
released unspecifically from the ferritin core it would catalyze 
- like any other form of adventitious cellular iron the for- 
mation of hydroxyl radicals via Haber-Weiss-Fenton reaction 
cycles [14]. The hydroxyl radical gives rise to a radical reac- 
tion chain inducing, e.g., DNA strand breaks [15,16] and gen- 
erating lipid peroxidation products [17]. Such a process even- 
tually could lead to cell death. 
Based on in vitro experiments it has been suggested that the 
release of iron from ferritin in vivo could be achieved by a 
variety of reductants including the catecholamine metabolite 
*Corresponding author. Fax: (49) (451) 500-4214. 
**Present address: MPI for Strahlenchemie, 45470 Mtilheim, Ger- 
many. 
Abbreviations: EPR, electron paramagnetic resonance; PBS, phos- 
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6 -OHDA [18], reactive oxgen species like superoxide anion 
[19,20], nitric oxide [20,21] and substances normally active 
as antioxidants like glutathione [22,23] and ascorbate [22]. 
Ascorbate is particularily interesting because of its hy- 
pothesized pro-oxidative activity in neuroblastoma tissue ori- 
ginating from the potentiating effect of ascorbate on com- 
monly used antitumourigenic agents like fluorouracil or 
bleomycin [24]. Further work demonstrated that ascorbic 
acid induces DNA strand breaks in neuroblastoma cells 
[25,26] and tissues [27]. These effects were especially pro- 
nounced in the presence of small amounts of H202 and tran- 
sition metals like iron [28,29]. Therefore, oxidative damage in 
neuroblastoma cells may be supported by an initial reductive 
release of iron from the large ferritin pool [11,12] and by high 
amounts of intracellularly produced H202 [26,30]. Both, fer- 
ritin [11,12] and H202 [26,30], are abundant in neuroblastoma 
cells at high concentrations. In addition, ascorbate can be 
accumulated in these cells reaching intracellular concentra- 
tions in the millimolar range [31]. Because neuroblastoma 
cells exhibit crucial prerequisites for ascorbic acid to act as 
a pro-oxidant his compound might be of aid in the treatment 
of that turnout. We have focused our interest on ascorbate 
because it acts either as an antioxidant in most normal tissues 
or as a pro-oxidant in neuroblastorna cells under certain con- 
ditions. 
So far, merely limited experimental evidence was found for 
the assumed pro-oxidative activity of ascorbic acid. In vitro, 
iron release was demonstrated by several assay systems like 
the ferrozine or bathophenanthroline assay [22,23]. Recently, 
we could get some hints that iron release by ascorbic acid is 
also possible in a cellular system using ~gFe-labeled ferritin. 
However, this was only practical in iron pretreated cells. 
Using the electron paramagnetic resonance (EPR) technique, 
we are now able to characterize ferritin iron clusters and 
changes in their size. 
2. Materials and methods 
2.1. Cell culture 
The cell line SK-N-SH [32] was procured from the American Type 
Culture Collection, USA. Cells were cultured in 5°/,, CO2 supplemen- 
ted air in RPMI 1640 medium containing 2 mM L-glutamine, 100 IU/ 
ml penicillin/streptomycin and 10% foetal calf serum (Biochrom, Ger- 
many). For EPR spectroscopy, 400x 106 cells were suspended in 50 ml 
culture medium and incubated with or without 1 mM ascorbate (Sig- 
ma, Germany) for 4 h at 37°C with sequential agitation. Afterwards, 
1 mM H202 (Merck, Germany) or, as a control, PBS (Biochrom) was 
added and incubated for further 10 rain, Thereafter, cells were washed 
twice with ice-cold PBS. Part of the cell pellet was used for protein 
and iron determination (see section 2.3). The residual cell material was 
diluted with 100 gl PBS. The cell number/ml of this suspension was 
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determined and 400 pl of it were filled in EPR tubes and frozen in 
liquid nitrogen until measurement. 
2.2. EPR measurement 
Measurements were made at 10 K, 73 K and 160 K at X-band (9.4 
GHz) using a cw-EPR spectrometer (Bruker ER200D) equipped with 
a helium-flow cryostat (Oxford Instruments ESR910). The data acqui- 
sition system, based on a personal computer, is our own development. 
The experimental spectra were numerically double-integrated. Prior to 
integration the experimental baselines were adjusted for offset and 
linear slope in the integration intervalls by means of computer gra- 
phics. Based on a test series, we estimated an error of 20%. 
2.3. Determination of  iron and protein concentrations 
The protein content of the samples was determined using the bi- 
cinchoninic acid reagent (Pierce, USA) following the instructions of 
the manufacturer. The iron content of SK-N-SH cells was determined 
according to Sofic et al. [33]. In brief, 70x 106 cells were resuspended 
in PBS and boiled for 10 min. The ice-chilled solutions were acidified, 
treated with 20 mM dithiothreitol (Serva, Germany) and 2 mg/ml 
ferrozine (Serva, Germany) and the absorbance was measured at 
562 nm in a Ultrospect 4050 photometer f om LKB Biochrom, Ger- 
many. Ferritin containing 12% iron (Serva, Germany) was used as a 
control. Iron concentrations were calculated using the extinction coef- 
ficient of 27,900 M -1 -cm 1. 
3. Results 
Electron paramagnetic resonance spectrometry (EPR) was 
used to analyse ferritin-bound iron in neuroblastoma SK-N- 
SH cells. Three independent sets of samples were prepared 
from different cultures yielding qualitatively the same EPR 
spectra but differing in protein and iron concentrations. Fig. 
1 displays EPR spectra of neuroblastoma cells recorded at 
various temperatures. The iron concentration of the sample 
was 49 gM and the protein content 133 mg/ml. At 15 K (Fig. 
1A), two spectral features can be observed at g--4.3 and 
around g = 2. The signal at g = 4.3 corresponds to ferric iron 
in a rhombic enviroment. Rhombic iron was found in all 
biological systems we have analysed so far: bacteria, fungi 
and animal cell lines. However, without a more detailed 
knowledge of the particular system, this signal cannot be at- 
tributed to a specific compound. Double integration of this 
signal gave a relative area of 160 arbitrary units (au). Around 
g- -2  several signals are found (relative area after double in- 
tegration: 174 au). We assume that these signals reflect a 
variety of iron and Cu compounds. One of the components 
probably represents an iron sulfur protein. At 10 K (data not 
shown) there is a weak signal at g = 6 reflecting an ferric iron 
compound of axial symmetry. This signal is typical for cyto- 
chromes. At 15 K this signal disappears. 
Ferritins, however, cannot be detected in EPR at low tem- 
peratures. In case, ferric iron particles are antiferromagneti- 
cally ordered (as in the iron core of ferritin), their EPR signals 
will broaden and decrease in intensity below the Ne61 (order- 
ing) temperature with decreasing temperature. The linewidth, 
DH, is given by: 
AH = AKVexp(KV/ksT)  (1) 
where A is a constant dependent upon the core size, K is the 
magnetic anisotropy constant per unit volume, V is the vo- 
lume of the particle, kB is the Boltzmann constant, and T the 
temperature [34,35]. 
Therefore, we have analysed the sample also at 73 K (Fig. 
1B) and 160 K (Fig. IC). The intensities of the EPR signals at 
g=4.3  (area after double integration: 90 au) and g=2 de- 
crease with increasing temperature as expected. However, an 
additional feature is visible at 73 K, a very broad derivative 
signal stretching over a field range of 350 mT in this measure- 
ment (double integration yields an area of 4018 au). At 160 K 
this feature is even more pronounced and dominates the spec- 
trum (4636 au) indicating the existence of antiferromagneti- 
cally ordered ferric iron in small particles. Therefore, we at- 
tribute this component o ferritin. The linewidth AH of 47.6 
mT at 160 K is close to that of isolated horse spleen ferritin. 
In Fig. 2, EPR spectra of neuroblastoma cells are shown 
which were treated 4 h with 1 mM ascorbic acid. The iron 
concentration of the sample was 42 gM and the protein con- 
tent was 127 mg/ml. At 15 K (Fig. 2A), again the same signals 
near g--4.3 and g=2 can be detected as in Fig. 1A. The same 
holds for the appearance of a broad signal at 73 K (double 
integration yields an area of 1656 au). However, this broad 
signal narrows considerably at 160 K (2040 au). The line 
width AH of 25.8 mT is almost half as broad as that of the 
untreated cell sample shown in Fig. 1C. According to Eqn. 1 
[35] and assuming the same anisotropy constant for sample 1 
and 2 we attribute the decreased linewidth to a smaller core 
size of ferritins. This change of core size is a consequence of 
ascorbate treatment. Hence, ascorbate is capable of mobiliz- 
ing iron from ferritin. Moreover, the relative area of the dou- 
ble integrated signals of ascorbate treated cells compared with 
that of the control displays the same trend (50% drop). 
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Fig. 1. EPR spectra of neuroblastoma SK-N-SH cells mesured at 
15 K (microwave frequency=9.428 GHz; microwave power=2.0 
mW/20 dB; modulation frequency =100 kHz; modulation ampli- 
tude = 1 mT. If not stated otherwise the EPR spectra in Figs. 2 and 
3 were measured under the same conditions), 73 K (microwave fre- 
quency=9.426 GHz), and 160 K (microwave frequency=9.428 
GHz). The broad signal observed at 160 K is attributed to ferritin 
(double integration spin density =4636 arbitrary units). 
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In Fig. 3 the EPR spectra of neuroblastoma cells are de- 
picted which were treated 4 h with 1 mM ascorbic acid and 
then for additional 10 min with 1 mM H202. The iron con- 
centration of the sample was 26 ~tM and the protein content 
was 60 mg/ml indicating the cell density was approximately 
half of that in sample 1 and 2. Consequently, only weak 
signals near g=4.3 and g=2 could be detected at 15 K 
(Fig. 3A). Again a very broad signal is observed at 73 K 
(area of 1529 au) and 160 K (area of 1917 au). At 160 K 
the signal width of 46 mT is similar to that of the untreated 
control thus indicating a core size which is larger than that 
which corresponds to the linewidth shown in Fig. 2C. At a 
first glance, the calculated spectral area of ascorbate/H202 
treated cells at 160 K is much too low to fit this model. 
However, taking into account he smaller number of cells in 
this sample three, the relative area should be corrected to 
approximately 3800 au which is within experimental error 
the same value as that obtained for untreated cells. 
4. Discussion 
Iron is an essential metal in all biological systems erving as 
a cofactor of many enzymes like ribonucleases, i ro~sul fur  
proteins and cytochromes. However, iron in its ferrous form 
may also be cytotoxic because of its reaction with H202 yield- 
ing various reactive oxygen species [36,38]. These naturally 
occurring oxygen metabolites are believed to have a dual 
role in the cellular metabolism: they are either involved in 
regulatory processes like the activation of NF-n-B [39,40] 
x,, 
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Fig. 2. EPR spectra of neuroblastoma SK-N-SH cells treated for 4 h 
with 1 mM ascorbic acid measured at 15 K (microwave fre- 
quency = 9.428 GHz), 73 K (microwave frequency =9.429 GHz), and 
160 K (microwave frequency=9.429 GHz). The ferritin signal (spin 
density--2040 arbitrary units) observed at 160 K is much sharper 
than in Fig. 1. 
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Fig. 3. EPR spectra of neuroblastoma SK-N-SH cells treated for 4 h 
with 1 mM ascorbic acid and subsequently for 10 min with 1 mM 
H202. Spectra were measured at 15 K (microwave frequency =9.432 
GHz; microwave power=20 gW/20 dB); 73 K (microwave fre- 
quency=9.428 GHz); and 160 K (microwave frequency=9.428 
GHz); spin density of the ferritin signal at 160 K=3800 arbitrary 
units (corrected value, see text). 
and the Bcl-2 protein preventing apoptosis [41], or they may 
induce oxidative damage to cell membranes or nucleic acids 
[42]. Normally, iron is stored in ferritin to prevent cell injury 
[13]. However, several reducing substances, among them as- 
corbic acid, are able to release iron from ferritin which was 
shown in in vitro assays [20,22]. 
In the present study we show that ascorbic acid decreases 
the size of the iron core of ferritin in situ which is reflected by 
a decrease of linewidth AH and also by drop of the relative 
area of the double integrated signal. These findings could in- 
dicate that a significant portion of iron in ascorbate treated 
cells is EPR-silent which might be attributed to the formation 
of high-spin Fe 2+. After additional treatment with H202 both, 
linewidth AH and area increase again. This could reflect the 
formation of large-size precipitates of ferric hydroxide origi- 
nating from reoxidized ferrous iron. If this is true the ob- 
served line shape is then a superposition of (modified) ferritin 
and of ferric hydroxide precipitates. 
The mechanism by which ascorbic acid releases iron from 
the ferritin core remains, however, unclear. Reduction of Fe 3+ 
to Fe 2+ in ferritin requires an agent exhibing a reduction po- 
tential ower than -230 mV at pH 7 [20]. The reduction poten- 
tial of ascorbic acid is + 166 mV [43]. Therefore ascorbic acid 
itself may not be the active releasing agent. However, ascorbic 
acid rapidly oxidizes in aqueous solution in the presence of 
oxygen and traces of metal ions [43]. One known intermediate 
of the oxygen/ascorbic a id reaction is the superoxide anion 
which can release iron from ferritin (E °' = -330 mV, [20]). 
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The results presented in this in situ EPR study provide 
evidence for the hypothesis that ascorbic acid can induce 
iron release from ferritin. Since neuroblastoma cells contain 
elevated iron levels (stored in ferritin) and produce high 
amounts of H202 [26,30], conditions for pro-oxidative cell 
injury can be generated by application of ascorbic acid. This 
may open new ways in cancer therapy of this hardly curable 
tumor in stage IV, especially in combination with some cyto- 
static drugs [24]. 
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